- Report
- November 2023
- 161 Pages
Global
From €2275EUR$2,500USD£1,933GBP
- Drug Pipelines
- September 2020
- 737 Pages
Global
From €2275EUR$2,500USD£1,933GBP
- Report
- March 2024
- 132 Pages
Middle East, Africa
From €1365EUR$1,500USD£1,160GBP
- Report
- February 2022
- 138 Pages
Global
From €13648EUR$14,995USD£11,592GBP
- Report
- October 2023
- 77 Pages
Global
From €3500EUR$4,119USD£3,077GBP
- Report
- October 2023
- 105 Pages
Global
From €3500EUR$4,119USD£3,077GBP
- Report
- May 2022
- 843 Pages
Global
From €2275EUR$2,500USD£1,933GBP
Mood stabilizers are a class of drugs used to treat mental disorders, such as bipolar disorder, depression, and anxiety. These drugs work by regulating the levels of neurotransmitters in the brain, which can help to reduce the intensity of mood swings and other symptoms associated with mental disorders. Commonly prescribed mood stabilizers include lithium, valproic acid, carbamazepine, and lamotrigine.
Mood stabilizers are an important part of the mental disorders drugs market, as they can help to reduce the severity of symptoms and improve quality of life for those affected. They are often used in combination with other medications, such as antidepressants, to provide a comprehensive treatment plan.
Some of the companies in the mood stabilizer market include AbbVie, AstraZeneca, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Novartis, Pfizer, and Teva Pharmaceuticals. Show Less Read more